Loading data for CMPX — first visit, this takes a few seconds.

提醒

Compass Therapeutics Inc. (CMPX)

NasdaqCM: CMPX · 实时价格 · USD

2.52

+0.09 (3.70%)

收盘价： Aug 27, 2026, 3:59 PM

2.50

-0.79%

盘后: 7:30 PM

股价、关键数字和最新消息，都在这一页。

3.70% (1D)

买价	2.51
市值	453.82M
营收（TTM）	n/a
净利润（TTM）	-73.45M
	0.82
	-0.39
	n/a
	-4.71
市净率（TTM）	2.73
市销率（TTM）	n/a
财报日期	Nov 5, 2026

卖价	3.09
成交量	1,935,409
20日均量	3,176,623
开盘价	2.44
前收盘价	2.43
日内区间	2.40 - 2.53
52周区间	1.61 - 6.88
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an Ig...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Apr 5, 2021

员工人数 39

交易所 NasdaqCM

股票代码 CMPX

官网 https://www.compasstherapeutics.com

公司完整简介

财务表现

2025年，Compass Therapeutics的营收为0，较上一年的850K下降-100%。净利润为-66.49M，增长34.66%。

财务报表

财报意外

Compass Therapeutics 已于 Aug 6, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.13 低于预期 -0.02, ， 7.14% 同比增长.

下次财报发布时间

Compass Therapeutics Inc. 的下次财报预计于 Nov 5, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

1月前 · Insider Monkey

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 4, Citizens reiterated a Market Outperform rating on the stock with a price tar...

2月前 · Insider Monkey

How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for...

2月前 · MarketBeat

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody...

3月前 · Insider Monkey

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D...

3月前 · Insider Monkey

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 ...

第 1 页，共 2 页

Compass Therapeutics Inc. (CMPX)